Back to top
more

Envista (NVST)

(Delayed Data from NYSE)

$21.10 USD

21.10
1,979,088

-0.03 (-0.14%)

Updated Sep 16, 2025 03:59 PM ET

After-Market: $21.50 +0.40 (1.90%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

New Strong Sell Stocks for December 6th

by Zacks Equity Research

BYND, NVST, FSTR, ZBH, and PHR have been added to the Zacks Rank #5 (Strong Sell) List on December 6, 2021.

Zacks Equity Research

New Strong Sell Stocks for November 29th

by Zacks Equity Research

DVA, NVST, WWD, PHR, and ROAD have been added to the Zacks Rank #5 (Strong Sell) List on November 29, 2021

Zacks Equity Research

Envista (NVST) Q3 Earnings Beat Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 12.50% and -10.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Envista (NVST) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Veeva Systems' (VEEV) Deal to Enhance Digital Clinical Trials

by Zacks Equity Research

Veeva Systems' (VEEV) partnership with Leo Pharma to significantly boost the clinical trial process for patients, sites and sponsors.

Zacks Equity Research

Here's Why You Should Hold on to NextGen (NXGN) Stock Now

by Zacks Equity Research

NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. However, intense competition woes linger.

Zacks Equity Research

Here's Why You Should Add Neogen (NEOG) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about Neogen (NEOG) on strength in its Food Safety and Animal Safety business segments.

Zacks Equity Research

Thermo Fisher (TMO) Expands Biologics Network With New Facility

by Zacks Equity Research

Thermo Fisher's (TMO) Lengnau site will offer biopharma companies a pathway from development to large-scale production.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock For Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on growth in the company's specialty digital solutions and a bullish 2021 outlook.

Zacks Equity Research

Bio Rad (BIO) Global Growth Strong, Expenses Continue to Rise

by Zacks Equity Research

Bio Rad (BIO) is witnessing strong growth in the biopharma market, riding on the Droplet Digital PCR platform.

Zacks Equity Research

Here's Why You Should Invest in Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.

Zacks Equity Research

Cardinal Health's (CAH) Unit to Aid Canadian Healthcare System

by Zacks Equity Research

Cardinal Health's (CAH) subsidiary to support the Canadian Healthcare system against COVID-19 with vaccination policy.

Zacks Equity Research

Cardiovascular Systems (CSII) Treats 1st Patient With ViperCross

by Zacks Equity Research

Cardiovascular Systems' (CSII) ViperCross offers the correct balance of support and flexibility to navigate tortuous anatomy and cross challenging lesions.

Zacks Equity Research

Here's Why You Should Invest in West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.

Zacks Equity Research

PacBio (PACB) Partners with ERGA, Boosts Biodiversity Research

by Zacks Equity Research

PacBio's (PACB) collaboration with ERGA will help scientists to take the first important step toward creating high-quality genetic maps of each plant and animal species in a reliable manner.

Zacks Equity Research

Quest Diagnostics' (DGX) Base Volumes Rise, Testing Recovers

by Zacks Equity Research

Contributions from new hospital lab management contracts as well as people returning to the healthcare system aid Quest Diagnostics (DGX).

Zacks Equity Research

Medtronic (MDT) Gets CE Mark for Radial Artery Access Portfolio

by Zacks Equity Research

Medtronic's (MDT) Rist Radial Access Catheters are indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature.

Zacks Equity Research

NEOGEN (NEOG) Inks Genomic Selection Deal With Hendrix

by Zacks Equity Research

Hendrix Genetics with the help of NEOGEN's (NEOG) Genomics will be able to genotype the elite animals in the population.

Zacks Equity Research

Here's Why You Should Invest in Quest Diagnostics (DGX) Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) backed by its strong second-quarter performance and recovery in the base testing business.

Zacks Equity Research

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Medtronic (MDT) owing to new product flow and strong market share gain across the company's businesses.

Zacks Equity Research

Medtronic (MDT) Hugo RAS System Used for 1st Clinical Procedure

by Zacks Equity Research

Medtronic's (MDT) Hugo RAS system is a modular, multi-quadrant platform intended for a broad range of soft-tissue procedures.

Kinjel Shah headshot

6 Low Price-to-Book Stocks to Increase Your Portfolio's Value

by Kinjel Shah

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

Zacks Equity Research

NVST or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVST vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

IDEXX (IDXX) CAG Placement Grows Globally Amid Cost Woes

by Zacks Equity Research

IDEXX's (IDXX) global reference lab revenues are growing organically, reflecting growth in the United States and the international markets.

Zacks Equity Research

Here's Why You Should Add Alcon Stock (ALC) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Alcon (ALC) backed by robust second-quarter performance and raised 2021 outlook.